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Osteoblastic differentiation is regulated by various factors, including hormones and transcription
factors. Runt-related transcription factor 2 (Runx2) is an essential player in osteoblastogenesis
and transactivates its molecular target by creating a protein complex with its hetero-dimeric part-
ner core binding factor beta (Cbfb). However, the molecular regulation of Cbfb expression remains
unknown. Here, we identified miR-145 as a crucial regulator of Cbfb expression. The expression of
miR-145 increased during osteoblastogenesis, indicating that miR-145 works as an inhibitor of
osteoblastogenesis. Stable expression of miR-145 decreased endogenous Cbfb expression and
inhibited osteoblastogenesis, in cooperation with miR-34c. Furthermore, miR-145 decreased bone
regeneration in vivo. Our results indicate that miR-145 physiologically regulates osteoblast differen-
tiation and bone formation via Cbfb expression by forming a regulatory microRNA network.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Skeletal development and bone regeneration depend on the
properties of osteoblasts derived from mesenchymal stem cells
(MSCs) [1–5]. Bone is routinely remodeled throughout life, requir-
ing the coordinated expression of many genes in response to many
physiological signals. Osteoblastic differentiation fromMSCs is reg-
ulated by multiple signaling pathways that are activated ligands
such as bone morphogenetic proteins (BMPs), fibroblast growth
factors (FGFs) and Wnts, which directly activate runt-related tran-
scription factor 2 (Runx2) [6–8]. Runx2 is an essential transcription
factor for osteoblastic differentiation and Runx2-knockout (KO)
mice die at birth due to the absence of osteoblasts [9–12]. Toactivate the transcription of its target genes, Runx2 requires core
binding factor beta (Cbfb), a co-transcription factor that enhances
the DNA binding of Runx2, although it does not bind DNA by itself
[13]. Indeed, Cbfb mutant mice develop skeletal dysplasia and die
at birth, displaying a phenotype reminiscent of Runx2-KO mice
[14–17].
MicroRNAs (miRNAs) are small non-coding RNAs that regulate
the expression of the target protein by inhibiting the translation
or accelerating the degradation of the transcript through binding
to the 30-UTR of those target genes [18]. MiRNAs are important reg-
ulators in various developmental, physiological and pathological
conditions [19–21]. Previous reports suggested that miRNAs are
also intimately involved in the osteoblast differentiation. For
instance, miR-206 inhibits osteoblast differentiation by suppress-
ing connexin43 [22]. MiR-29 and -218 promote osteoblast
differentiation by modulating Wnt signaling [23–25]. MiR-26a
and -100 functionally inhibit osteoblast differentiation by target-
ing BMP signaling [26,27]. Moreover, numerous studies have
revealed that multiple miRNAs including miR-204, -133, -23a,
-30c, -34c, -133a, -135a, -137, -204, -205, -217, and -338 inhibit
osteoblast differentiation by targeting Runx2 [28–31]. However,
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remain unknown.
In this study, we identified miR-145 as an miRNA that targets
Cbfb. We also demonstrated that miR-145 inhibits osteoblastic dif-
ferentiation in cooperation with miR-34c, which targets Runx2. We
propose that osteoblast differentiation is regulated by an miRNA
network system targeting the Runx2-Cbfb transcription factor
complex rather than a single microRNA targeting a single protein.
2. Materials and methods
2.1. Reagents and plasmid
Mimic miR-145, miR-34c and control miRNA were purchased
from Dharmacon. A genomic fragment of miR-145 and a cDNA
fragment of Cbfb were amplified by PCR and cloned into pcDNA3.
2.2. Cell culture and transfection
MC3T3-E1 was cultured in a-modified Eagle’s medium
(a-MEM) supplemented with 10% FBS. HEK293 cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FBS. The human mesenchymal stem cells (RCB2080;
Riken BRC) were maintained using the MSCGMMesenchymal Stem
Cell Growth Medium BulletKit (Lonza). Cells were transiently
transfected with mimic miR-145 (20 nM) or miR-34c (50 nM)
using HiPerFect transfection reagent (Qiagen) according to the
manufacturer’s instructions. For osteoblastic differentiation, cells
were cultured in osteogenic medium (Ob medium with 0.1 mg/
mL ascorbic acid, 10 mM b-glycerophosphate) changed every
2 days. After 7 days, osteoblast differentiation was confirmed by
measuring the of alkali phosphatase (ALP) activity and the expres-
sion of osteoblast marker genes as previously described [32]. ALP
activity was measured using p-nitrophenyl phosphatase
hexahydrate (Sigma). In brief, cells were lysed in 0.2% Triton-X
solution. After sonication, the ALP activity in the cell lysates was
determined and normalized to protein concentration. For von
Kossa staining, MC3T3-E1 cells were cultured in Ob medium. After
21 days, cells were fixed in 4% paraformaldehyde (PFA) in phos-
phate buffered saline (PBS) and stained with 5% silver nitrate solu-
tion. After washing in distilled water, cells were incubated with 5%
sodium thiosulfate solution. In vitro osteoclast differentiation was
accomplished as previously described [33]. Briefly, bone marrow
cells (3  105 cells per cm2) from the femurs of six-to eight-
week-old mice were cultured in a-MEM supplemented with FBS
in the presence of human macrophage colony-stimulating factor
(M-CSF, 10 ng/mL, R&D Systems) for 2 days and then differentiated
into osteoclasts by exposure to human RANKL (50 ng/mL, Pepro-
tech) and M-CSF for 3 days. Subsequently, the differentiation of
osteoclasts was evaluated by TRAP staining. In brief, osteoclasts
were fixed in 4% PFA in PBS. Fixed cells were permeabilized with
acetone/ethanol and stained with Fast Red Violet LB Salt (Sigma)
in TRAP solution [33]. To determine miR-145 expression, primary
osteoblasts were isolated from calvaria of post-natal day 3 (P3)
mice by digestion medium (0.5 mg/mL collagenase P and 0.05%
trypsin in aMEM) and cultured in a-MEM supplemented with
10% FBS. After 3 days, the RNA was extracted from these cells.
2.3. Luciferase assay
Mouse Cbfb 30-UTR regions were amplified by PCR and cloned
into pCMV-luc reporter plasmid [22]. MiR-145 binding (50-TCTA
GAAACTGGAGGCGCGCCAACTGGACTGCAG-30) or mutated oligonu-
cleotides (50-TCTAGAAGATCTCGGCGCGCCAGATCTCCTGCAG-30)
were cloned into pCMV-luc. HEK293 cells were plated in 24-well
plates at a concentration of 1.3  105 cells/well. Cells wereco-transfected with reporter plasmids (100 ng/well) and either
the miR-145 expression vector (100 ng/well) or the control plas-
mid (100 ng/well) using Lipofectamine 2000 (Invitrogen). The
phRL-tk plasmid (10 ng/well) was used as an internal control. We
used the empty vector to equalize the amount of plasmid trans-
fected in each experiment. After 48 h of transfection, firefly or
Renilla luciferase activities were quantified using a dual-
luciferase assay system (Promega).
2.4. Quantitative real-time PCR analysis
MiRNA and total RNA from tissues and cultured cells were
extracted using the miRNeasy mini kit (Qiagen). RNAs were reverse
transcribed using the TaqMan miRNA reverse transcription kit
(Applied Biosystems) or the ReverTra Ace qPCR RT Kit (TOYOBO)
according to the manufacturer’s instructions. Relative miRNA
expression was determined by quantitative real-time PCR (qPCR)
using miR-145- or miR-34c-specific TaqMan probes (Applied
Biosystems). Osteoblast marker qPCRwas performed using the Bril-
liant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent Technolo-
gies). All qPCR reactions were performed using the Mx3000P real-
time PCR system (Agilent Technologies). We used snoRNA202 (for
miRNA) and GAPDH (for osteoblast marker gene) expression as
internal controls. The following primers were used: Alpl S, 50-ACAC
CTTGACTGTGGTTACTGCTGA-30 and Alpl AS, 50-CCTTGTAGCCAGG
CCCGTTA-30; Bglap S, 50-TCTGACAAAGCCTTCATGTCCA-30 and Bglap
AS, CGGTCTTCAAGCCATACTGGTC-30; GAPDH S, 50-ACCCAGAAGAC
TGTGGATGG-30 and GAPDH AS, 50-CACATTGGGGGTAGGAACAC-30.
2.5. Immunoblotting
Immunoblot analysis was performed according to a standard
protocol. Cells were lysed in TNE buffer (10 mM Tris–HCl (pH
7.5), 0.15 M NaCl, 1 mM EDTA, and 1% Nonidet P-40) containing
protease inhibitors. Lysates were subjected to SDS–polyacrylamide
gel electrophoresis and transferred to a PVDF membrane.
Immunoblotting was performed using anti-Cbfb antibody (MBL;
D127-3), anti-Runx2 antibody (MBL; M130-3), and b-actin
antibody (Sigma; A2228).
2.6. Bone marrow ablation
Mice were anesthetized intraperitoneally with 400 mg/kg
trichloroacetaldehyde monohydrate (Chloral Hydrate; Wako Pure
Chemical). After removing the hair from both hind limbs, the bone
marrow of both femora were ablated as described previously
[32,34]. Briefly, bilateral longitudinal incisions were made on the
knees of each mouse to expose the femoral condyle by dislocating
the patella. A hole was made at the intercondylar notch of the
femur using a dental drill. A 0.6 mm diameter Kirschner wire
was inserted in the proximal end of the femur to confirm complete
marrow ablation by radiography. Then, 20 lg of mimic miR-145 or
the control was complexed with atelocollagen (Kohken) as
described previously [35] and injected into the bone marrow. After
injection, the dislocated patella was repositioned and the skin was
sutured. Mice were euthanized at day seven after ablation and
micro-CT analyses were performed. Animal experiments were per-
formed with the approval of the Animal Study Committee of Tokyo
Medical and Dental University School of Medicine and conformed
to the relevant guidelines and laws.
2.7. Statistical analysis
We performed statistical analysis using the Tukey–Kramer and
Student’s t test. Values were considered to be statistically signifi-
cant at P < 0.05. All data are reported as the mean ± S.D.
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3.1. Identification of miRNA targeting Cbfb
First, we performed a comprehensive analysis of osteoblastic
miRNAs using MC3T3-E1 osteoblastic cells. In parallel with this
analysis, we also performed an miRNA database search to identify
miRNAs that target Cbfb (Fig. 1A).
Out of the number of miRNAs that exhibited altered expression
during osteoblast differentiation, we focused on miR-145 because
it fulfilled two prerequisites of this study: it is expressed at
substantial levels in osteoblasts and it targets Cbfb.
First, to confirm that Cbfb is a true target of miR-145, we per-
formed a luciferase activity assay using a reporter plasmid in
which the putative miR-145 binding sites of the Cbfb 30UTR were
cloned into the 30UTR of the luciferase gene (Fig. 1B). In accordance
with the in silico prediction, forced expression of miR-145 signifi-
cantly decreased the luciferase activity, whereas a mutation in the
miR-145 binding site of the Cbfb 30UTR abrogated the response to
miR-145 (Fig. 1C). Moreover, miR-145 decreased the luciferaseA B
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Fig. 1. Identification of Cbfb-targeting miRNA. (A) List of top 10 putative Cbfb-targeting
the miR-145 target site in the 30-UTR of Cbfb mRNA and the reporter construct. (C and D)
cells were co-transfected with the reporter plasmid and miR-145 or the control. After 24 h
E1 cells were transfected with mimic miR-145 or control. After 48 h, quantitative real-tim
performed. The data are expressed as the mean ± S.D. of three independent experimentactivity of a construct harboring 1 kbp of the Cbfb 30UTR fragment,
which contains the aforementioned putative miR-145 binding site
(Fig. 1D).
More importantly, the overexpression of miR-145 decreased
Cbfb protein expression without overtly affecting Cbfb mRNA
expression (Fig. 1E). These results indicate that miR-145 is a ‘‘bona
fide” regulator of Cbfb.
3.2. Suppression of osteoblast differentiation by miR-145
Given that Cbfb is essential for proper osteoblast differentiation,
we next studied whether miR-145 regulates osteoblast differentia-
tion through the modulation of Cbfb expression. We first analyzed
the expression profile of miR-145 throughout the whole body and
observed that it is ubiquitously expressed in various tissues includ-
ing bone, especially in osteoblasts (Fig. 2A). Moreover, miR-145
expression was induced during the time course of osteoblast differ-
entiation, indicating that miR-145 physiologically affects osteo-
blast differentiation (Fig. 2B). Therefore, we next studied the
effect of miR-145 on osteoblast differentiation by transfecting5’-ACCAGAAACUGUGACAACUGGAG-3’
3’-UCCCUAAGGACCCUUUUGACCUG-5’
bfb 3’ UTR
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Repression of Luc reporter activities mediated by the 30-UTR of Cbfb mRNA. HEK293
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s (n = 3). *P < 0.05.
T. Fukuda et al. / FEBS Letters 589 (2015) 3302–3308 3305MC3T3-E1 or hMSC cells with miR-145. As expected, the overex-
pression of miR-145 inhibited osteoblast differentiation as shown
by the decrease in the ALP activity and the expression of osteoblast
markers such as alpl and bglap (Fig. 2C and D). Moreover, forced
expression of a miR-145 mimic led to a significant decrease in
matrix mineralization (Fig. 2E). To address whether the inhibition
of osteoblast differentiation by miR-145 is due to Cbfb downregu-
lation, we restored the expression of Cbfb in miR-145 transfected
cells. Indeed, the decrease in ALP activity was rescued by the forced
expression of Cbfb (Fig. 2F). In contrast to osteoblast differentia-
tion, miR-145 did not affect osteoclast differentiation (Fig. 2G).Fig. 2. Effect of miR-145 on osteoblast differentiation. (A) Expression pattern of miR-14
primary osteoblasts and osteoclasts. (B) Expression profiles of miR-145 during osteoblas
indicated time. (C and D) Effect of miR-145 on osteoblast differentiation. Cells were tr
expression (D) were analyzed. (E) von Kossa staining of matrix mineralization on day
MC3T3-E1 cells were transfected with the indicated plasmids. After 7 days, the ALP a
osteoclasts were transfected with mimic miR-145 or control. Subsequently, TRAP-posit
three independent experiments (n = 3). *P < 0.05.These results suggest that miR-145 inhibits osteoblast differentia-
tion through Cbfb expression.
3.3. miR-145 and miR-34c cooperatively inhibit osteoblast
differentiation
Cbfb is required for Runx2-dependent transcription during
osteoblast differentiation. Therefore, we hypothesized that miRNA
targeting Runx2 and miR-145, which targets Cbfb, may also coordi-
nately to regulate osteoblast differentiation. miR-34c inhibits
osteoblast differentiation by regulating Runx2 expression [30].5 determined by real-time PCR. Total RNA was isolated from the indicated tissue,
t differentiation. MC3T3-E1 cells were treated with differentiation medium for the
ansfected with mimic miR-145 or control. ALP activity (C) and osteoblast marker
21. (F) Cbfb rescues the inhibitory effect of miR-145 on osteoblast differentiation.
ctivity was analyzed. (G) Effect of miR-145 on osteoclast differentiation. Primary
ive multi-nuclear cells were counted. The data are expressed as the mean ± S.D. of
3306 T. Fukuda et al. / FEBS Letters 589 (2015) 3302–3308Similar to miR-145, the miR-34c expression was also induced dur-
ing osteoblast differentiation, and transfection with miR-34c
decreased ALP activity (Fig. 3A). The co-transfection of the miR-
145 mimic and the -34c mimic inhibited ALP activity synergisti-
cally, albeit not significant, (Fig. 3B) compared with miR-145
mimic or miR-34c alone. MiR-145 and -34c decreased Cbfb or
Runx2 protein expression, respectively (Fig. 3C). These results indi-
cate that miR-145 and -34c cooperatively inhibit osteoblast differ-
entiation through Cbfb and Runx2 protein expression.
3.4. miR-145 affects physiological bone formation in vivo
Next, to address the functional role of miR-145 in vivo, we
ablated the bone marrow of mouse femurs and then treated them
with miR-145. Treatment with mimic miR-145 reduced bone
regeneration compared with mice treated with control scrambled
miRNA (Fig. 4A and B). These results indicate that miR-145 also
participates in the bone regeneration process in adult mice.A
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Fig. 3. miR-145 and miR-34c cooperatively inhibit osteoblast differentiation. (A)
Expression profiles of miR-34c during osteoblast differentiation. MC3T3-E1 cells
were treated with differentiation medium for the indicated amount of time. (B)
Effects of miR-145 and miR-34c on osteoblast differentiation. MC3T3-E1 cells were
transfected with mimic miR-145, miR-34c and control. After 7 days, ALP activity
was analyzed. (C) MC3T3-E1 cells were transfected with mimic miR-145, miR-34c
and control for 48 h. Western blot was used to detect the levels of Cbfb and Runx2
protein expression. The data are expressed as the mean ± S.D. of three independent
experiments (n = 3).4. Discussion
Bone homeostasis is strictly regulated by many physiological
signals. In particular, osteoblasts play an important role in skeletal
development and bone formation. Understanding the regulatory
mechanism of osteoblast differentiation is important for the devel-
opment of new therapeutic strategies to treat degenerative bone
diseases such as osteoporosis. In this study, we investigated the
miRNA-mediated regulation of Cbfb expression in osteoblast dif-
ferentiation. We demonstrated that miR-145 directly regulates
Cbfb expression. MiR-145 expression increased during osteoblast
differentiation, and the ectopic expression of miR-145 suppressed
osteoblast differentiation. The overexpression of Cbfb rescued the
inhibitory effect of miR-145 in osteoblast differentiation. Finally,
miR-145 affected the physiological process of bone regeneration
in vivo.
Cbfb is a non-DNA-binding transcription factor that allosteri-
cally potentiates the DNA binding of Runx family proteins and
plays an essential role in Runx2-dependent skeletal development.
However, the mode of action of Cbfb remains unclear. Although
Cbfb has been shown to stabilize Runx2 by inhibiting
polyubiquitination-mediated proteasomal degradation [36], CbfbA
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micro-CT images of bone regeneration after femoral bone marrow ablation in mimic
control and miR-145-treated and control-treated mice at 2 months. (B) Bone
volume/tissue volume (BV/TV; %). Measurement areas were indicated in (A). The
data are expressed as the mean ± S.D. (n = 5). *P < 0.05.
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haploinsufficiency does not elicit cleidocranial dysplasia [16]. Thus,
Cbfb is important but not essential for osteoblast differentiation by
itself, and it requires the presence of Runx2 to exert its effects on
osteoblasts. Runx2 is a central regulator of osteoblast differentia-
tion, and many miRNAs have been shown to affect osteoblast
differentiation by modulating the Runx2 protein.
We identified that miR-145 directly regulates Cbfb expression
by binding the putative 30-UTR target site, resulting in the inhibi-
tion of Cbfb mRNA translation. We also showed that the overex-
pression of miR-145 inhibits osteoblast marker expression. These
results suggest that miR-145 regulates runx2-dependent osteo-
blast differentiation through Cbfb. Indeed, the restoration of Cbfb
expression was sufficient to rescue the abnormal osteoblast
differentiation.
Interestingly, previous studies have shown that miR-145 regu-
lates Osx protein expression, i.e., Osx is a target of miR-145 [38].
Osx is a zinc finger transcription factor that is essential for skeletal
development and bone formation [39], and this gene is down-
stream of Runx2 in the transcriptional regulation of osteoblast dif-
ferentiation. Thus, miR-145 act as a major regulator of osteoblast
differentiation by affecting essential transcription factors, i.e., Cbfb
and Osx. A mouse model lacking miR-145 would be useful to
demonstrate the physiological importance of miR-145 for osteo-
blast differentiation in vivo.
Cbfb also forms a heterodimer with Runx1, and this complex is
essential for hematopoiesis in the fetal liver. In addition, chromo-
somal translocation involving Cbfb is a major cause of hematopoi-
etic diseases, such as inv (16) acute myeloid leukemia (AML).
Indeed, both Cbfb- and Runx1-deficient mice develop impaired
hematopoiesis [40,41]. We showed that miR-145 is ubiquitously
expressed in many tissues including liver and bone, indicating that
miR-145 may also be involved in the hematopoiesis and develop-
ment of AML through Cbfb expression.
One microRNA targets a number of genes, and each target gene
is regulated by many microRNAs. Thus, the relationship between
an miRNAs and a target genes is a many-to-many correspondence,
not a one-to-one correspondence. Recently, the miR-34 family has
been reported to act as regulators of osteoblastogenesis.
Osteoblast-specific deletion of miR-34 revealed that miR-34b and
c play important roles in osteoblast proliferation by suppressing
Cyclin D1, CDK4 and CDK6 and differentiation by repressing SATB2
[42]. These reports combined with our results suggest that
miR-145 and -34c regulate osteoblastogenesis through a number
of target genes.
In this study, we demonstrated that different microRNAs coop-
eratively regulate a common signaling pathway by affecting one
specific transcription factor complex, i.e., Runx2-Cbfb. Indeed,
transfecting multiple miRNAs targeting Runx2-Cbfb synergistically
decreased osteoblast differentiation.
Thus, beyond regulating the gene transcription/translation by
many-to-many correspondence, multiple microRNAs cooperatively
regulate one physiological event, i.e., osteoblast differentiation, by
affecting the same transcription factor complex.
Interestingly, recent reports showed that Cbfb stabilizes the
Runx2 protein and thus stimulates osteoblast differentiation [36].
Together with our results showing that miR-145 regulates
osteoblast differentiation through Cbfb, these results clearly
demonstrate the importance of Cbfb in osteoblast differentiation.
Until now, the molecular mechanism of the regulation of miR-
145 expression during osteoblast differentiation has remained
unclear. Previous reports showed that the promoter activity of
miR-145 was repressed by OCT4 in human embryonic stem (ES)
cells [43]. OCT4 is a fundamental transcription factor that regulates
the self-renewal and differentiation of ES cells and is expressed in
bone marrow-derived mesenchymal stem cells [44]. Therefore,Oct4 is a plausible candidate miR-145 regulatory factor. Further
study will be required to elucidate the detailed regulatory mecha-
nism of miR-145 expression.
In summary, we have demonstrated that miR-145 is a novel
regulator of Cbfb expression and that it acts as a global regulator
of osteoblast differentiation. Our findings suggested that the phar-
macological inhibition of miR-145 could lead to a therapeutic
approach to treat degenerative bone diseases, such as osteoporosis.
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